argenx SE announced that data from its Phase 3 ADHERE trial evaluating VYVGART Hytrulo in patients with chronic inflammatory demyelinating polyneuropathy were presented for the first time to the medical community during the Clinical Trials Plenary Session at the American Academy of Neurology Annual Meeting in Denver, CO.
